acne%20vulgaris
ACNE VULGARIS
Acne vulgaris is a chronic inflammatory dermatosis which is notable for open and/or closed comedones (blackheads and whiteheads) and inflammatory lesions including papules, pustules or nodules.
Mild acne has <20 comedones or <15 inflammatory lesions or <30 total lesion count.
Moderate acne has 20-100 comedones or 15-20 inflammatory lesions or 30-125 total lesion count.
Severe papules/pustules or nodulocystic acne is the acne resistant to topical treatment or if scarring/nodular lesions are present.

Classification

Classification by Severity

  • Usually overestimated by patient and underestimated by physician
Mild* Moderate** Severe***
Comedones <20 20-100 >100
Papules/Pustules <15 15-50 >50
Nodules/Cysts 0 <5 >5
Total Lesion Count <30 30-125 >125
*Includes comedonal & mild papulopustular acne
**Further subdivided into moderate papulopustular acne & moderate nodular acne
***Further divided into severe papulopustular acne, severe nodular acne, & conglobate acne


Other Considerations

  • Grading schemes that rely on the above lesion counts are usually of greater use in clinical studies rather than clinical practice
  • May be better to focus on the most severe lesions present
    • Proper treatment of the most severe lesions usually covers all lesser lesions

History

  • History of past treatments
  • In most cases, there is no need to look for underlying cause, which may be found in patients >20 years old and in resistant acne cases

Physical Examination

  • Diagnosis is usually confirmed based on the morphology of the lesions and their site of distribution

Types of Acne Lesions

  • Comedonal (non-inflammatory)
    • Closed (whitehead) or open (blackhead) lesions
  • Papulopustular (inflammatory)
    • Papule: Small bump <5 mm in diameter
    • Pustule: Smaller bump with core of purulent material
  • Nodular (inflammatory)
    • Represents severe acne, manifested as nodules & deep pustules of >5 mm diameter
    • Conglobate acne is a severe form of nodular acne where the lesions are firm, inflamed & painful measuring >10 mm

Site of Distribution

  • Lesions typically concentrate in the centrofacial areas
    • Forehead, nose, chin
  • May eventually involve other areas containing sebaceous glands
    • Face, ears, neck, chest, shoulders, back, scalp

Evaluation

Acne Grading Systems
  • Currently there is no recommended universal grading/classifying system for acne
  • Several scoring methods are being used by different associations, grading & lesion counting being the most commonly used methods
    • Number of lesions, type of acne, disease severity, anatomical site/s, & propensity for scarring should be considered when determining acne score for management purposes
    • Some scoring methods being used include the Echelle de Cotation des Lesions d’Acne (ECLA) or Acne Lesion Score Scale, Leeds technique, post acne hyperpigmentation index (PAHPI), Comprehensive Acne Severity System (CASS), & the Acne Quality of Life Scale (AQOL) among others
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, Yesterday
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.